Real World Assessment of Biological Treatment of Inflammatory Bowel Disease at an Austrian Referral Centre: The ULTIMATE Study

Gröchenig, HP; Walter, E.; Redl, A; Bresztowanszky, M; Steidl, K; Siebert, F; Novacek, Gottfried

doi:10.1055/s-0039-1691861

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Already the groups adapted to the medication or just needing to optimize it, follow the general statistics presented in the large studies as ACCENT II 15 . A study published in the European Crohn’s and Colitis Organization (ECCO) 10 shows that the rate of hospitalizations and complications increases relatively in patients needing medication change, as it also coincides with our data. In the same study 10 , it was shown that medication dose optimization was required in 34.9% of patients with first-line treatment and 37.1% in patients with other treatment lines, a result very similar to the present study in which 39% of patients required dose or interval optimization of the medication.…”

Section: Discussionsupporting

confidence: 91%

Predictive Factors for Loss of Response to Anti-TNF in Crohn’s Disease

Santos¹,

Santos

Santos³

et al. 2020

ABCD, arq. bras. cir. dig.

View full text Add to dashboard Cite

Background: Anti-TNF drugs are a fundamental part of the treatment of Crohn’s disease (CD), so identifying factors related to loss of response is of great importance in clinical practice. Aim: Identify potential factors related to loss of response to anti-TNF agents in Crohn’s disease patients. Methods: This is a prospective study of CD patients attending a specialized outpatient clinic using a specific form, including patients with more than one year of follow-up on anti-TNF (Infliximab, Adalimumab or Certolizumab pegol). The information obtained was tabulated and analyzed to identify possible reasons for the loss of response to anti-TNF agents; results were submitted to statistical analysis by chi-square teste considering significant p<0.05. Results: Sixty-four patients were included, most of them females (56.3%), predominant age group between 26 and 55 years, of whom 25 required optimization, 23 remained in remission with the usual dose and interval, and 16 required switch; most of those who needed switch had hematological problems such as anemia and/or had already undergone surgical treatment for CD. Conclusions: Anemia and prior CD surgery have been linked to loss of anti-TNF response.

show abstract

Section: Discussionsupporting

confidence: 91%